SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma

References

• Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806–813.
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461–466.
   PubMed Web of Science ®Google Scholar
• Linke F, Harenberg M, Nietert MM, et al. Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma. Leukemia. 2017;31(2):361–372.
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658–1667.
   PubMed Web of Science ®Google Scholar
• Lwin T, Crespo LA, Wu A, et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin’s B lymphoma cells from apoptosis. Leukemia. 2009;23(1):170–177.
   PubMed Web of Science ®Google Scholar
• Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155(1):53–64.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016;104(3):281–292.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–1562.
   PubMed Web of Science ®Google Scholar
• Vegliante MC, Palomero J, Perez-Galan P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175–2185.
   PubMed Web of Science ®Google Scholar
• Palomero J, Vegliante MC, Eguileor A, et al. SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. Leukemia. 2016;30(7):1596–1599.
   PubMed Web of Science ®Google Scholar
• Palomero J, Vegliante MC, Rodriguez ML, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235–2247.
   PubMed Web of Science ®Google Scholar
• Balsas P, Palomero J, Eguileor A, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130(4):501–513.
   PubMed Web of Science ®Google Scholar
• Kuo PY, Leshchenko VV, Fazzari MJ, et al. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Oncogene. 2015;34(10):1231–1240.
   PubMed Web of Science ®Google Scholar
• Gustavsson E, Sernbo S, Andersson E, et al. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Mol Cancer. 2010;9(1):187.
   PubMed Web of Science ®Google Scholar
• Conrotto P, Andreasson U, Kuci V, et al. Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo. Mol Oncol. 2011;5(6):527–537.
   PubMed Web of Science ®Google Scholar
• Kuci V, Nordstrom L, Conrotto P, et al. SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma. Leuk Lymphoma. 2016;57(8):1883–1892.
   PubMed Web of Science ®Google Scholar
• Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. 2008;143(2):248–252.
   PubMed Web of Science ®Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. Br J Haematol. 2014;166(1):98–108.
   PubMed Web of Science ®Google Scholar
• Yang W, Wang Y, Yu Z, et al. SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. Int J Hematol. 2017;106(2):212–220.
   PubMed Web of Science ®Google Scholar
• He J-X, Xi Y-F, Su L-P, et al. Association of SOX11 gene expression with clinical features and prognosis of mantle cell lymphoma. Eur Rev Med Pharmacol Sci. 2018;22(9):2556–2563.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408–1418.
   PubMed Web of Science ®Google Scholar
• Rosenstein Y, Park JK, Hahn WC, et al. CD43, a molecule defective in Wiskott–Aldrich syndrome, binds ICAM-1. Nature. 1991;354(6350):233–235.
   PubMed Web of Science ®Google Scholar
• Rupniewska ZM, Roliński J, Bojarska-Junak A. UniversalCD43 molecule. Postepy Hig Med Dosw. 2000;54(5):619–638.
   PubMedGoogle Scholar
• Hardy RR, Carmack CE, Shinton SA, et al. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991;173(5):1213–1225.
   PubMed Web of Science ®Google Scholar
• Dragone LL, Barth RK, Sitar KL, et al. Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival. Proc Natl Acad Sci U S A. 1995;92(2):626–630.
   PubMed Web of Science ®Google Scholar
• Ostberg JR, Dragone LL, Driskell T, et al. Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency. J Immunol. 1996;157(11):4876–4884.
   PubMed Web of Science ®Google Scholar
• Misawa Y, Nagaoka H, Kimoto H, et al. CD43 expression in a B cell lymphoma, WEHI 231, reduces susceptibility to G1 arrest and extends survival in culture upon serum depletion. Eur J Immunol. 1996;26(11):2573–2581.
   PubMed Web of Science ®Google Scholar
• Lynch EF, Jones PA, Swerdlow SH. CD43 and CD5 antibodies define four normal and neoplastic B-cell subsets: a three-color flow cytometric study. Cytometry. 1995;22(3):223–231.
   PubMedGoogle Scholar
• de Leon ED, Alkan S, Huang JC, et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin’s lymphomas of small lymphocytes. Mod Pathol. 1998;11(11):1046–1051.
   PubMed Web of Science ®Google Scholar
• Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111(4):488–494.
   PubMed Web of Science ®Google Scholar
• Ma XB, Zheng Y, Yuan HP, et al. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. Hum Pathol. 2015;46(4):593–599.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Iqbal J, Fu K, et al. CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. Br J Haematol. 2013;162(1):87–92.
   PubMed Web of Science ®Google Scholar
• Ma X-B, Zhong Y-P, Zheng Y, et al. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med. 2018;7(9):4284–4295.
   PubMed Web of Science ®Google Scholar
• Xu S, Yuting D, Huo Z, et al. SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours. Histopathology. 2019;74(3):391–405.
   PubMed Web of Science ®Google Scholar
• Weilin T, Yaqi D, Rumeng Y, et al. Foam cell-derived CXCL14 multi-functionally promotes atherogenesis and is a potent therapeutic target in atherosclerosis. J Cardiovasc Transl Res. 2019;13(2):215–224.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307–5316.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner WS, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119(18):4215–4223.
   PubMed Web of Science ®Google Scholar
• Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica. 2012;97(9):1422–1430.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang L, Li J, et al. SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients. Am J Surg Pathol. 2019;43(5):710–716.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Atarashi K, Umemoto E, et al. CD43 functions as a ligand for E-selectin on activated T cells. J Immunol. 2005;175(12):8042–8050.
   PubMed Web of Science ®Google Scholar
• Miura Y, Mizutani C, Nishihara T, et al. Adhesion via CD43 induces Syk activation and cell proliferation in TF-1 cells. Biochem Biophys Res Commun. 2001;288(1):80–86.
   PubMed Web of Science ®Google Scholar
• Layseca-Espinosa E, Pedraza-Alva G, Montiel JL, et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol. 2003;74(6):1083–1093.
   PubMed Web of Science ®Google Scholar
• Myklebust JH, Brody J, Kohrt HE, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017;129(6):759–770.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011;21(5):308–312.
   PubMed Web of Science ®Google Scholar
• Ostberg JR, Barth RK, Frelinger JG. The Roman god Janus: a paradigm for the function of CD43. Immunol Today. 1998;19(12):546–550.
   PubMedGoogle Scholar
• Anzai N, Gotoh A, Shibayama H, et al. Modulation of integrin function in hematopoietic progenitor cells by CD43 engagement: possible involvement of protein tyrosine kinase and phospholipase C-gamma. Blood. 1999;93(10):3317–3326.
   PubMed Web of Science ®Google Scholar